488 GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy

BackgroundSeveral PD-1 antibodies have been approved as anti-cancer therapies which work by blocking the interaction of PD-1 with its ligand PD-L1, thus restoring anti-cancer T cell activities. However, cross-reactive anti-PD-1 antibodies binding to both human and pre-clinically relevant animal mode...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal for immunotherapy of cancer 2022-11, Vol.10 (Suppl 2), p.A509-A509
Hauptverfasser:	Kim, Haemi, Kyoung-Jin, Kim, Myeong Jin Yoon, Choih, Jenny, Eun Ji Cho, Hak-Jun, Jung, Lee, Kwanghyun, Kim, Jayoung, Park, Chae Gyu, Han, Sungho, Bae, Donggoo, Park, Heungrok
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Immunotherapy Monoclonal antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!